Published: 12 September 2016
Author(s): Henrik Frederiksen, Waleed Ghanima
Section: Letter to the Editor

Despite therapeutic achievements like rituximab and thrombopoeitin receptor agonists, corticosteroids remain the mainstay of first line treatment for immune thrombocytopenia (ITP) [1,2]. However, only few randomized trials have been performed on steroids [3–7] and data on sustainability of response are conflicting. Pulsed high dose (HD) dexamethasone has been suggested to have higher response rates than standard treatment with prednisone but response is temporary [7]. Results on corticosteroid response among unselected adults are lacking.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.